IRON 50.49 Disc Medicine, Inc.
| Range: | 25.6-77.6 | Vol Avg: | 204056 | Last Div: | 0 | Changes: | 0.28 |
| Beta: | 0.18 | Cap: | 1.42B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Aug 12 2020 | Empoloyees: | 78 | ||
| CUSIP: | CIK: | 0001901203 | ISIN: | US2546041011 | Country: | US | |
| CEO: | Dr. John D. Quisel Esq., J.D., Ph.D. | Website: | https://www.discmedicine.com | ||||
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Stock Details
Neutral 0.03
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a c...
globenewswire.com·Fri Oct 11 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow